• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

饮食、生活方式和药物干预后体重减轻和反弹的预测。

Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.

机构信息

Clinical Unit in Cambridge, GlaxoSmithKline, Cambridge University Hospital NHS Trust, Cambridge, UK.

出版信息

Clin Pharmacol Ther. 2012 Jun;91(6):1027-34. doi: 10.1038/clpt.2011.333. Epub 2012 Feb 15.

DOI:10.1038/clpt.2011.333
PMID:22336590
Abstract

To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine. This was followed by 12 weeks of observation. The best of the "baseline covariates" models was one that incorporated intervention group and baseline homeostasis model assessment-estimated insulin resistance (HOMA(IR)). It predicted week 12 weight change with R(2) of 0.38 and root mean square error (√MSE) of 2.92 kg. An alternative model incorporating baseline fat mass plus change in weight and HOMA(IR) at week 4 improved the prediction (R(2), 0.67, √MSE, 2.19 kg). We could not identify a satisfactory model to predict weight regain. We conclude that prediction of weight loss over 12 weeks is significantly improved when short-term weight change is incorporated into the model. This information could be utilized to forecast the success of a weight-loss program and to motivate and contribute to innovative designing of obesity trials.

摘要

为了开发预测体重减轻和反弹的统计模型,我们分析了一项针对 60 名肥胖患者的门诊研究的表型反应,这些患者被随机分为三组 12 周干预措施之一:单独节食(-600 卡路里)、节食加运动和节食加西布曲明。随后进行了 12 周的观察。“基线协变量”模型中最好的一个是包含干预组和基线稳态模型评估估计的胰岛素抵抗(HOMA(IR))的模型。它预测第 12 周的体重变化,R²为 0.38,均方根误差(√MSE)为 2.92 公斤。另一个包含基线脂肪量和第 4 周体重变化以及 HOMA(IR)的模型改善了预测(R²,0.67,√MSE,2.19 公斤)。我们无法确定一个满意的模型来预测体重反弹。我们的结论是,当将短期体重变化纳入模型时,对 12 周内的体重减轻预测会显著改善。这些信息可用于预测减肥计划的成功,并为肥胖试验的创新设计提供动力和帮助。

相似文献

1
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.饮食、生活方式和药物干预后体重减轻和反弹的预测。
Clin Pharmacol Ther. 2012 Jun;91(6):1027-34. doi: 10.1038/clpt.2011.333. Epub 2012 Feb 15.
2
Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.在专科医生指导的极低热量饮食后,在全科医生环境中使用西布曲明进行长期体重减轻维持:一项双盲、安慰剂对照、平行组研究。
Eur J Clin Nutr. 2005 Aug;59 Suppl 1:S31-8; discussion S39. doi: 10.1038/sj.ejcn.1602172.
3
Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine.极低热量饮食后体重减轻的长期维持:西布曲明疗效和耐受性的随机双盲试验
Am J Med. 1999 Feb;106(2):179-84. doi: 10.1016/s0002-9343(98)00411-2.
4
Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial.生活方式改变在肥胖药物治疗中的益处:一项随机试验。
Arch Intern Med. 2001 Jan 22;161(2):218-27. doi: 10.1001/archinte.161.2.218.
5
Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.使用西布曲明和奥利司他治疗谁会减重?治疗成功的心理关联因素。
Diabetes Obes Metab. 2008 Jun;10(6):498-505. doi: 10.1111/j.1463-1326.2007.00740.x. Epub 2007 Jun 26.
6
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.低热量饮食联合西布曲明治疗对超重及肥胖多囊卵巢综合征女性激素和代谢特征的影响:一项随机、为期24周的研究
Int J Obes (Lond). 2008 Apr;32(4):692-9. doi: 10.1038/sj.ijo.0803777. Epub 2007 Dec 11.
7
[Pharmacological therapy of obesity].[肥胖症的药物治疗]
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S.
8
[Evaluation of the sibutramine effect on satiety with a visual analogue scale in obese adolescents].[使用视觉模拟量表评估西布曲明对肥胖青少年饱腹感的影响]
Arq Bras Endocrinol Metabol. 2005 Apr;49(2):286-90. doi: 10.1590/s0004-27302005000200016. Epub 2005 Sep 12.
9
Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.西布曲明联合代餐疗法用于肥胖患者的体重减轻及维持
Obesity (Silver Spring). 2007 Jun;15(6):1464-72. doi: 10.1038/oby.2007.175.
10
Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.西布曲明治疗肥胖症2年期间体重减轻及维持的预测因素。欧洲多中心STORM试验结果。西布曲明减肥及维持试验。
Int J Obes Relat Metab Disord. 2001 Apr;25(4):496-501. doi: 10.1038/sj.ijo.0801481.

引用本文的文献

1
Plasma Levels of Triglycerides and IL-6 Are Associated With Weight Regain and Fat Mass Expansion.血浆甘油三酯和白细胞介素 6 水平与体重反弹和脂肪量扩张有关。
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1920-1929. doi: 10.1210/clinem/dgac198.
2
Baseline anandamide levels and body weight impact the weight loss effect of CB1 receptor antagonism in male rats.基线阿南达胺水平和体重影响雄性大鼠中CB1受体拮抗作用的体重减轻效果。
Endocrinology. 2015 Apr;156(4):1237-41. doi: 10.1210/en.2014-1730. Epub 2014 Dec 30.
3
Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.
μ-阿片受体拮抗剂GSK1521498对享乐性和 consummatory 饮食行为的影响:暴饮暴食肥胖受试者的机制研究证据
Mol Psychiatry. 2013 Dec;18(12):1287-93. doi: 10.1038/mp.2012.154. Epub 2012 Nov 13.
4
Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.阿片μ受体拮抗作用对肥胖暴食个体认知的影响。
Psychopharmacology (Berl). 2012 Dec;224(4):501-9. doi: 10.1007/s00213-012-2778-x. Epub 2012 Jul 3.